TY - JOUR
T1 - Molecular epidemiology of JCV genotypes in patients and healthy subjects from Northern Italy
AU - Zanotta, Nunzia
AU - Delbue, Serena
AU - Rossi, Tatiana
AU - Pelos, Giorgio
AU - D'Agaro, Pierlanfranco
AU - Monasta, Lorenzo
AU - Ferrante, Pasquale
AU - Comar, Manola
PY - 2013/7
Y1 - 2013/7
N2 - Very little is known about JCV infection and genotype distribution with respect to the different demographic and clinical characteristics of the Italian population. A cross-sectional study was carried out on the prevalence of JCV genotypes in 323 Caucasian subjects (mean age: 37.5 years, range: 2-70 years). Urine samples from 200 immunocompromised patients, including patients affected by Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), colon cancer, inflammatory diseases and Progressive Multifocal Leukoencephalopathy (PML), and 123 immunocompetent individuals were tested by quantitative real time PCR. Sequencing of the JCV viral protein 1 (VP1) and transcriptional control region (TCR) was performed. In this series, the overall prevalence of JCV excretion was 32.8% without significant differences between males and females. JCV was detected in 39.5% of patients and in 22% of healthy individuals (P=0.004). The most prevalent JCV genotype excreted was genotype 1 (69.8%), followed by genotype 2 (22.6%) and genotype 4 (7.5%). Distribution of genotypes between patients and healthy subjects showed a statistically significant difference for the type 1 compared to the other variants (P
AB - Very little is known about JCV infection and genotype distribution with respect to the different demographic and clinical characteristics of the Italian population. A cross-sectional study was carried out on the prevalence of JCV genotypes in 323 Caucasian subjects (mean age: 37.5 years, range: 2-70 years). Urine samples from 200 immunocompromised patients, including patients affected by Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), colon cancer, inflammatory diseases and Progressive Multifocal Leukoencephalopathy (PML), and 123 immunocompetent individuals were tested by quantitative real time PCR. Sequencing of the JCV viral protein 1 (VP1) and transcriptional control region (TCR) was performed. In this series, the overall prevalence of JCV excretion was 32.8% without significant differences between males and females. JCV was detected in 39.5% of patients and in 22% of healthy individuals (P=0.004). The most prevalent JCV genotype excreted was genotype 1 (69.8%), followed by genotype 2 (22.6%) and genotype 4 (7.5%). Distribution of genotypes between patients and healthy subjects showed a statistically significant difference for the type 1 compared to the other variants (P
KW - Immunocompromised and healthy subjects
KW - JCV
KW - Subtypes
UR - http://www.scopus.com/inward/record.url?scp=84878216148&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878216148&partnerID=8YFLogxK
U2 - 10.1002/jmv.23585
DO - 10.1002/jmv.23585
M3 - Article
C2 - 23918546
AN - SCOPUS:84878216148
VL - 85
SP - 1286
EP - 1292
JO - Journal of Medical Virology
JF - Journal of Medical Virology
SN - 0146-6615
IS - 7
ER -